Pfizer Settles Thousands of Zantac Cancer Lawsuits

The pharmaceutical giant reaches agreements over alleged cancer risks linked to its heartburn medication, Zantac, amid ongoing legal battles.

Pfizer has agreed to settle over 10,000 lawsuits claiming the company failed to disclose cancer risks associated with Zantac.
The settlements do not fully resolve Pfizer’s liability, as many cases remain pending across various U.S. courts.
Financial terms of the settlements have not been disclosed, maintaining uncertainty around the total cost to Pfizer.
The FDA had previously identified NDMA, a potential carcinogen, in Zantac, leading to a recall and reformulation of the drug.
Market impacts from the litigation saw a significant drop in collective market value for Zantac's manufacturers in 2022, though some recovery has been noted.